ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR), 2015, we would like to inform you that the RTA of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for loss of share certificate from the legal representative of the claimant. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday, February 8, 2024
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2023. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from December 16, 2023 to February 10, 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Permission To Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Andexanet Alfa Powder For Solution For Infusion 200 Mg (Andexxa)
This is to inform you that AstraZeneca Pharma India Limited has received permission to Import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Andexanet alfa powder for solution for infusion 200mg (Andexxa). ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication of Postal Ballot Notice dated December 21, 2023. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated January 3, 2024 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants), Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We are enclosing herewith the Postal Ballot Notice dated December 21, 2023 being sent to the members of the Company to their registered email address, seeking approval of the members for the special business as set out therein. The Notice is being sent to the members whose names appear in the Register of Members/ Record of Depositories as on the cut-off date being Friday, December 29, 2023. The e-voting period commences on Monday, January 8, 2024 (9:00 am IST) and ends Tuesday, February 6, 2024 (5:00 pm IST).
AstraZeneca To Buy Cancer Drug Developer For Up To $1.2 Billion
AstraZeneca Plc agreed to acquire Chinese cell therapy developer Gracell Biotechnologies Inc. for as much as $1.2 billion as the British drug giant bolsters its bets on medical innovation in the world's second-biggest economy. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that the Company has received a draft order for the assessment unit being passed under Section 144C(1) read with Section 143(3) of the Income Tax Act, 1961 for the assessment year 2021-22. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Additional Director (Non-Executive)
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of of Ms. Sylvia Lorena Varela Ramon (DIN: 10410837), as an Additional Director (Non-Executive) of the Company with effect from December 21, 2023.
AstraZeneca Pharma to launch breast cancer drug, shares jump 6%
The pharma company will launch Enhertu, a breast cancer drug, in January 2024 in India.